TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01030068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga twice weekly

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness
Description: Health and wellness classes twice weekly
Study: NCT03770702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statins
Description: Atorvastatin
Study: NCT03482232

Intervention type: DRUG
Intervention: Benzodiazepines
Description: Benzodiazepines for insomnia, agitation or delirium in people older than 65

Intervention type: DRUG
Intervention: Non-steroidal anti-inflammatory drugs
Description: Non-steroidal anti-inflammatory drugs in patients with cardiovascular disease, chronic kidney disease, hypertension, heart failure or liver cirrhosis

Intervention type: DRUG
Intervention: paracetamol
Description: paracetamol 1g for more than 3 days

Intervention type: DRUG
Intervention: Antimicrobial agent
Description: antibiotic in acute bronchitis when the patient does not suffer from COPD, heart failure, diabetes or kidney disease or is undergoing active chemotherapy

Intervention type: DRUG
Intervention: Lipid-lowering drug
Description: Lipid-lowering drugs in patients older than 75 years without previous cardiovascular events

Intervention type: DIAGNOSTIC_TEST
Intervention: Prostate cancer
Description: Screening for prostate cancer in asymptomatic patients
Study: NCT01030068

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation therapy
Description: Smoking cessation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking cessation therapy
Description: Smoking cessation therapy
Study: NCT03482232

Intervention type: RADIATION
Intervention: Lumbago
Description: image tests in non-specific lumbago

Intervention type: DRUG
Intervention: Antimicrobial agent
Description: antibiotics for pharyngitis (infants)

Intervention type: DRUG
Intervention: Mucolytic
Description: mucolytics, antitussives or antibiotics for upper respiratory infections (infants)

Intervention type: DRUG
Intervention: Ibuprofen and paracetamol
Description: treatment with ibuprofen and paracetamol (infants)
Study: NCT01554709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aortic Cannulas (CardioGard)
Description: Comparison of aortic cannulas during by pass surgery
Study: NCT00938327

Intervention type: BIOLOGICAL
Intervention: Rotarix™
Description: Two doses of oral vaccine.
Study: NCT01554709

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aortic Cannulas (CardioGard)
Description: Comparison of aortic cannulas during by pass surgery
Study: NCT00814983

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Naive T-cell Depleted Stem Cell Transplant
Description: The Isolex device from Baxter will be used to perform the cell selection procedure. After the CD34 selected stem cell graft has been collected, the CD34- flow-throughfraction will be depleted of CD45RA+ naive T-cells. To accomplish this, a second immunomagnetic bead selection process will be performed on the Isolex device, making use of a GMP-grade murine anti-human CE45RA antibody. This depleted fraction will comprise the donor lymphocyte inoculum given to the transplant recipient along with the stem cell component on day 0 of transplant.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem Cell Transplant No Manipulation
Description: These patients will be transplanted with unmanipulated peripheral blood stem cells.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isolex device from Baxter
Study: NCT04398225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine
Description: Extended release capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine
Description: Extended release capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine
Description: Extended release capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine
Description: Extended release capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine
Description: Extended release capsule
Study: NCT02174770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR) Training
Description: This is a modality of physical therapy where during low-load resistance activity, the venous return of blood from an extremity is limited only during the duration of the exercise. This can be accomplished through multiple means. For the purposes of our study, we will use an inflatable tourniquet.
Study: NCT01874743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg/day
Description: All patients must take 20mg/day of rosavastatin during 3 months
Study: NCT01593189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KITS Program
Description: This is a 4-month psychosocial intervention for children with developmental disabilities and behavior problems who are entering kindergarten and their caregivers. The intervention begins in the summer before kindergarten. The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 times per week in the fall); and (b) a bi-monthly psychoeducational support group to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques
Study: NCT02174770

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Flow Restriction (BFR) Training
Description: This is a modality of physical therapy where during low-load resistance activity, the venous return of blood from an extremity is limited only during the duration of the exercise. This can be accomplished through multiple means. For the purposes of our study, we will use an inflatable tourniquet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR) Training
Description: This is a modality of physical therapy where during low-load resistance activity, the venous return of blood from an extremity is limited only during the duration of the exercise. This can be accomplished through multiple means. For the purposes of our study, we will use an inflatable tourniquet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard ACSM-guided strength training
Description: This is the standard protocol to be used for post-operative and other physical therapy patients for rehabilitation. It includes the use of American College of Sports Medicine-guidelines for how much weight to use during the strength training portion of the rehabilitation.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard ACSM-guided strength training
Description: This is the standard protocol to be used for post-operative and other physical therapy patients for rehabilitation. It includes the use of American College of Sports Medicine-guidelines for how much weight to use during the strength training portion of the rehabilitation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard ACSM-guided strength training
Description: This is the standard protocol to be used for post-operative and other physical therapy patients for rehabilitation. It includes the use of American College of Sports Medicine-guidelines for how much weight to use during the strength training portion of the rehabilitation.
Study: NCT01424137

Intervention type: DEVICE
Group type: OTHER
Intervention: Easyhaler type A
Description: Easyhaler type A inhaler, 3 consecutive inhalations

Intervention type: DEVICE
Group type: OTHER
Intervention: Easyhaler type B
Description: Easyhaler type B inhaler, 3 consecutive inhalations

Intervention type: DEVICE
Group type: OTHER
Intervention: Diskus inhaler
Description: Diskus inhaler, 3 consecutive inhalations
Study: NCT00595465

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Japanese Encephalitis purified inactivated vaccine
Description: IC51 6 mcg i.m. injection on Day 0 and Day 28

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Japanese Encephalitis purified inactivated vaccine
Description: IC51 6 mcg i.m. injection on Day 0 and Day 28
Study: NCT02559856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Study: NCT00595465

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Japanese Encephalitis purified inactivated vaccine
Description: IC51 6 mcg i.m. injection on Day 0 and Day 28
Study: NCT02559856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Study: NCT01355666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DermaTherapy® Linen and underpads.
Description: DermaTherapy® Linen is a 100% synthetic silk-like fabric technology designed to provide a cleaner, drier and smoother surface between the skin and support systems for a healthy micro-climate.~Subjects in the DermaTherapy® Linen Group are compared to subjects receiving usual care - bed linen made of cotton-blend fabrics.
Study: NCT04280380

Intervention type: DIAGNOSTIC_TEST
Intervention: Real time PCR
Description: At inclusion, serum samples will be collected to determine CMV serological status. Plasma samples will be collected weekly for CMV PCR analysis. Antibodies for CMV will be assessed using a commercial enzyme immunoassay kit for detection of total antibodies to CMV (LIAISON CMV IgG assay, DiaSorin S.p.A). DNA will be extracted in 200 μL of plasma eluted in 60 μL of elution buffer using a NucliSENS easyMAG system (bioMérieux, Boxtel, The Netherlands). Samples will be amplified using Affigene CMV Trender diagnostic assay (Cepheid AB, Bromma, Sweden), according to the manufacturer instructions. Amplification will be performed on a MX3000P instrument (Stratagene Instruments Systems, La Jolla, CA, USA). Samples with \>500 copies/mL of plasma will be considered positive.
Study: NCT04507100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: World Health Organization Health Promoting Schools
Description: Healthy eating: regulation and monitoring of food sold in school cafeterias, healthy eating behavior change campaign, provision of healthy breakfasts.~Physical activity: hourly active breaks during classes, quality physical education, active recess, and extra-curricular leisure activities and tournaments.~Healthy hydration: access to water fountains and regular monitoring of water safety, regulation and monitoring of beverages sold in the school, and social marketing campaign promoting drinking plain water.~Other cross-sectional activities: Referral of children identified as living with underweight, overweight, or obesity, training for school directors, teachers and parents, establishment of school objectives to become a health promoting school, monitoring progress, and publicly acknowledging school progress in becoming a health promoting school.
Study: NCT01298531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: etanercept 50 mg subcutaneous (SC) injections once weekly for 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: etanercept
Description: etanercept 50 mg subcutaneous (SC) injections once weekly for 8 weeks following the prior 8 weeks of placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo subcutaneous (SC) injections once weekly for 8 weeks.
Study: NCT03487523

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Message
Description: As already stated

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Message
Description: As already stated
Study: NCT03326726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% CHG
Description: Chlorhexidine Gluconate
Study: NCT04342273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356
Description: KW-6356 will be administered once daily as therapeutic at Day 1 through Day 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356
Description: KW-6356 will be administered once daily as supratherapeutic dose at Day 1 through Day 7

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once daily at Day 1 through Day 7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Placebo will be administered once daily at Day 1 through Day 6, followed by Moxifloxacin once daily at Day 7.
Study: NCT00632840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin and fenofibrate
Description: atorvastatin (40mg/day) fenofibrate (200mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin and fenofibrate
Description: atorvastatin (40mg/day) fenofibrate (200mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin and fenofibrate
Description: atorvastatin (40mg/day) fenofibrate (200mg/day)
Study: NCT00967252

Intervention type: DRUG
Intervention: Atorvastatin
Description: Atorvastatin 10 mg daily or equivalent dose in another statin

Intervention type: DRUG
Intervention: Atorvastatin
Description: Atorvastatin 20 mg daily or equivalent dose in another statin

Intervention type: DRUG
Intervention: Atorvastatin
Description: Atorvastatin 40 mg daily or equivalent dose in another statin
Study: NCT00910702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: foldable capsular vitreous body(FCVB)
Description: the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB) after PPV
Study: NCT03914820

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC CO2 surgery
Description: Prophylactic surgery plus HIPEC CO2 performed with mitomycin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard surgery
Description: Standard surgery without HIPEC CO2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: Prophylactic surgery plus HIPEC CO2 performed with mitomycin
Study: NCT02883582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxyhydrogen
Description: Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxygen
Description: oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
Study: NCT00884182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine
Description: 0.5 mL, Intramuscular
Study: NCT01921270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose - AbobotulinumtoxinA
Description: Participants will receive low dose AbobotulinumtoxinA injections. Location of injections will be determined by the clinician to treat the individual's dystonic symptom.~Muscles that may be included for in injection for OMD with Jaw Closing:~Medial Pterygoid 50 units, Masseter 25 units~Muscles that may be included in injection for OMD with Jaw Opening:~Lateral Pterygoid 50 units, Anterior digastrics 10 units~Muscle that will be included in injection for OMD with Tongue Protrusion:~Genioglossus 7.5 units
Study: NCT04263662

Intervention type: OTHER
Intervention: Analgesia-Sedation algorithm
Description: The analgesia-sedation algorithm is a suggested protocol for approach to providing analgesia and sedation to patients admitted to the pediatric ICU who are newly intubated. The approach focuses on using dexmedetomidine as the primary sedative, non-opioids as the primary analgesia, then stepwise approach to adding in adjunctives (e.g. opioids, non-benzodiazepines) with the intention of minimizing benzodiazepine exposure and utilizing minimal-dose effective analgesia/sedative dosing.
Study: NCT02512692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIR-Spheres microspheres (Yttrium-90 Microspheres)
Description: On Day 3 or 4 of cycle 1 90Y TARE will be administered
Study: NCT02266498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBB 515 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBB 515 BS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard breakfast (40 g fat)
Study: NCT02242188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron
Description: Ferric pyrophosphate (powder preparation in sachets: Actiferol, SunActive Fe, Sequoia, Poland) in a single daily dose. Three doses will be used: 7 mg for infants up to 7 kg of body weight, 10 mg for infants from 7 to 10 kg of body weight, and 15 mg for those exceeding the weight of 10 kg. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.~The intervention will last from 4 months to 9 months of age.
Study: NCT00967252

Intervention type: DRUG
Intervention: Atorvastatin
Description: Atorvastatin 80 mg daily or equivalent dose in another statin

Intervention type: OTHER
Intervention: Control
Description: No statin being taken
Study: NCT03751982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Electrical Neuromodulation (TES)
Description: TES phase-aligned with slow waves or not
Study: NCT02242188

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin (packed in identical sachets as active products)
Study: NCT03751982

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Electrical Neuromodulation (TES)
Description: TES phase-aligned with slow waves or not
Study: NCT02150863

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrapulse Carbon Dioxide Laser

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrapulse Carbon Dioxide Laser

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cellutome epidermal harvesting system
Study: NCT02624856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Liposomal bupivacaine (EXPAREL®) 133 mg in 10 mL for quadriceps sparing femoral nerve block and 133 mg in 20 mL for posterior knee compartment periarticular injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine plus dexamethasone
Description: Bupivacaine HCl 0.5% 10 mL plus dexamethasone 2 mg for quadriceps sparing femoral nerve block and bupivacaine HCl 0.25% plus dexamethasone 2 mg for posterior knee compartment periarticular injection
Study: NCT03323255

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repeated transcranial magnetic stimulation continuous theta-burst stimulation
Description: cTBS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM repeated transcranial magnetic stimulation
Description: SHAM stimulation
Study: NCT01855464

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wedge resection
Description: Complementary to parietal pleurectomy lung tissue is resected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: parietal pleurectomy
Description: The parietal pleura is resected for treating primary pneumothorax.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: parietal pleurectomy
Description: The parietal pleura is resected for treating primary pneumothorax.
Study: NCT02479269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise for 8 weeks
Study: NCT00331864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Study: NCT04432974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic closed-loop anesthesia
Description: Total intravenous anesthesia performed with the ACTIVA automatic control system
Study: NCT02937571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT03094988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive and physical prehabilitation
Description: Participants engage in cognitive and physical training daily for approximately 2-4 weeks prior to surgery.

Intervention type: OTHER
Group type: OTHER
Intervention: Active attention control
Description: Participants will be provided with personal health educational materials and access to the control version of cognitive training program.
Study: NCT01355120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab monotherapy 3mg/kg by four infusion every 3 weeks
Study: NCT02600065

Intervention type: OTHER
Intervention: Blood draw and MRI
Description: The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw and MRI from patients at several time points during and after radio(chemo)therapy.
Study: NCT03749291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Obemat2.0 therapy
Description: Lifestyle (diet \& physical activity) structured recommendations through a motivational interview.~Duration: 12(+3) months Description: 1 visit/month \& 3 Workshops in primary care centers Providers: pediatricians and nurses trained to perform motivational interview The interviews are structured as follows: First, checking the accomplishment of objectives to motivate the participant. Second, a specific topic per visit is explained to the participant. Third, a task related to the topic (i.e. to plan a weekly menu for the family) is given to be brought back at the next visit. 4th. Objectives about diet, weight \& physical activity are defined to be accomplished until the next visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Clinical Practice
Description: Lifestyle (diet and physical activity) Duration: 12 (+3) months Description: 1visit/month to the primary care centers. Providers: pediatricians \& nurses. Children assigned to the control group receive the usual treatment conducted in primary care centers based on the Clinical Practice Guidelines on the Prevention and Treatment of Child and Adolescent Obesity \[Spanish Ministry of Science and Innovation\], 2009). At visits, the family receive recommendations to carry out a balanced diet, to provide a moderate energy reduction from the previous intake. An increase in physical activity, both in terms of leisure activity, as sports is advised.
Study: NCT02249520

Intervention type: OTHER
Group type: OTHER
Intervention: PET-MR imaging on Biograph mMR scanner
Description: Participants will undergo PET-MR imaging on the Biograph mMR scanner to evaluate the technical aspects of the total acquisition protocol directly post clinical administration of FDG, thus removing the requirement for additional radioisotope.

Intervention type: OTHER
Group type: OTHER
Intervention: MR-only imaging on Biograph mMR scanner
Description: Participants will undergo MR-only imaging to test the technical aspects of the MR-only protocol on the Biograph mMR scanner. No drug administered.

Intervention type: OTHER
Group type: OTHER
Intervention: MR imaging on the Siemens Vida 3T MR scanner
Description: Participants will undergo MR imaging to test the technical aspects of the MR protocol on the Vida MR scanner